Denmark ends the year with two new drug recommendations and one rejection
The Danish Medicines Council has concluded its December meeting, and has given its nod to two companies, while one left empty-handed. New highly anticipated guidelines for a spinal muscular atrophy treatment were also presented.
by albert rønning-andersson, translated by daniel pedersen
On Wednesday, pharmaceutical companies AstraZeneca and Recordati found their stockings full, as the Danish Medicines Council, which is responsible for recommending the medicines the Danish hospital system can take into use, had left application approvals for them both.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Denmark rejects Gilead and Eisai cancer drugs
For subscribers
Denmark recommends Lundbeck migraine treatment
For subscribers
